Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug
October 28, 2021
Merck KGaA taps CytoReason's machine learning platform to profile immuno-oncology drug
apark
Tue, 10/19/2021 – 16:24
Read the source article at fiercebiotech.com
2021-10-19 21:24:43
